Paxman
Research Paxman (PAX.ST) on Bullrun: market cap SEK 1.55B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPAX.ST
- ExchangeSSME
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Market capSEK 1.55B
- Financial periodQ1 2026
- RevenueSEK 89.56M
- Net income-SEK 125.00K
- Free cash flow-SEK 6.27M
- Gross margin66.4%
Valuation Snapshot
latest market cap is SEK 1.55B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 313.35M | -SEK 16.12M | -SEK 14.89M | 66.6% | -0.76 | SEK 120.83M | SEK 13.01M | SEK 405.16M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-06 | SEK 1.55B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Paxman
Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia. It also engages in the development of a medical cryocompression device for the prevention of chemotherapy-induced peripheral neuropathy. The company was founded in 1996 and is based in Karlshamn, Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Paxman's market cap?
Paxman's market capitalization is SEK 1.55B.
What does Paxman do?
Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia. It also engages in the development of a medical cryocompression device for the prevention of chemotherapy-induced peripheral neuropathy. The company was founded in 1996 and is based in Karlshamn, Sweden.